T2 Biosystems (TTOO) to Release Earnings on Monday

T2 Biosystems (NASDAQ:TTOO – Get Rating) will release its earnings data after the market closes on Monday, May 15th. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

T2 Biosystems Stock Performance

TTOO opened at $0.28 on Friday. T2 Biosystems has a fifty-two week low of $0.26 and a fifty-two week high of $15.00. The firm’s fifty day moving average is $0.42 and its 200 day moving average is $1.12. The stock has a market cap of $5.72 million, a price-to-earnings ratio of -0.02 and a beta of 0.35.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of T2 Biosystems in a research note on Sunday, May 7th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $2.50.

Institutional Trading of T2 Biosystems

Several hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its stake in T2 Biosystems by 449.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 538,540 shares of the medical equipment provider’s stock worth $61,000 after purchasing an additional 440,531 shares in the last quarter. Jane Street Group LLC purchased a new stake in T2 Biosystems in the 3rd quarter worth $28,000. Virtu Financial LLC lifted its stake in T2 Biosystems by 1,763.1% in the 2nd quarter. Virtu Financial LLC now owns 323,427 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 306,067 shares in the last quarter. Finally, State Street Corp lifted its stake in T2 Biosystems by 11.4% in the 1st quarter. State Street Corp now owns 646,500 shares of the medical equipment provider’s stock worth $339,000 after purchasing an additional 66,052 shares in the last quarter.

About T2 Biosystems

(Get Rating)

T2 Biosystems, Inc engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm’s products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel.